The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea

  • Kim, Cheolsu (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Lee, Ho Sup (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Min, Chang-Ki (Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Lee, Je Jung (Department of Hematology-Oncology, Chonnam National University Hwasun Hospital) ;
  • Kim, Kihyun (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yoon, Dok Hyun (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Eom, Hyeon Seok (Department of Internal Medicine, National Cancer Center) ;
  • Lee, Hyewon (Department of Internal Medicine, National Cancer Center) ;
  • Lee, Won Sik (Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Shin, Ho-Jin (Department of Internal Medicine, Pusan National University Hospital) ;
  • Lee, Ji Hyun (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Park, Yong (Department of Internal Medicine, Korea University College of Medicine) ;
  • Jo, Jae-Cheol (Department of Hematology and Oncology, Ulsan University Hospital) ;
  • Do, Young Rok (Department of Internal Medicine, Keimyung University School of Medicine) ;
  • Mun, Yeung-Chul (Department of Internal Medicine, Ewha Womans University School of Medicine)
  • Received : 2014.09.05
  • Accepted : 2014.10.15
  • Published : 2015.09.01
⟨ Previous Next ⟩

Abstract

Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, ${\beta}2$-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count >$100{\times}10^9/L$ and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.

Keywords

References

  1. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968-3977. https://doi.org/10.1182/blood-2007-10-117457
  2. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stemcell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-2085. https://doi.org/10.1016/S0140-6736(10)61424-9
  3. Morgan GJ, Davies FE. Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 2013;88 Suppl 1:S14-S22. https://doi.org/10.1016/j.critrevonc.2013.05.012
  4. Moreau P, Touzeau C. Initial treatment of transplant candidates with multiple myeloma. Semin Oncol 2013;40:585-591. https://doi.org/10.1053/j.seminoncol.2013.07.006
  5. Ozaki S, Shimizu K. Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future. Biomed Res Int 2014;2014:394792.
  6. Ahn SY, Jung SH, Joo YD, et al. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Ann Hematol 2014;93:1571-1577. https://doi.org/10.1007/s00277-014-2067-3
  7. Minarik J, Sandecka V, Maisnar V, et al. 10 Years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leuk Res 2013;37:1063-1069. https://doi.org/10.1016/j.leukres.2013.06.019
  8. Vande Broek I, Jacobs P. Continuous treatment in multiple myeloma: the future? Transfus Apher Sci 2013;49:147-150. https://doi.org/10.1016/j.transci.2013.07.017
  9. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124-127. https://doi.org/10.3324/haematol.11644
  10. Copur S, Kus S, Kars A, Renda N, Tekuzman G, Firat D. Lactate dehydrogenase and its isoenzymes in serum from patients with multiple myeloma. Clin Chem 1989;35:1968-1970.
  11. Engelhardt M, Terpos E, Kleber M, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014;99:232-242. https://doi.org/10.3324/haematol.2013.099358
  12. Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 2009;46:110-117. https://doi.org/10.1053/j.seminhematol.2009.02.004
  13. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-737.
  14. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007;137:240-243. https://doi.org/10.1111/j.1365-2141.2007.06561.x
  15. Strasser-Weippl K, Ludwig H. Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation. Leuk Lymphoma 2014;55:2520-2524. https://doi.org/10.3109/10428194.2014.891025
  16. Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol 2008;141:792-798. https://doi.org/10.1111/j.1365-2141.2008.07123.x
  17. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420. https://doi.org/10.1200/JCO.2005.04.242
  18. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854. https://doi.org/10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
  19. Lim JH, Seo EJ, Park CJ, et al. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities. Eur J Haematol 2014;92:313-320. https://doi.org/10.1111/ejh.12257
  20. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32:587-600. https://doi.org/10.1200/JCO.2013.48.7934
  21. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88:360-376. https://doi.org/10.1016/j.mayocp.2013.01.019
  22. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226-235.
  23. Oh S, Koo DH, Kwon MJ, et al. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Ann Hematol 2014;93:1353-1361. https://doi.org/10.1007/s00277-014-2057-5
  24. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063-6073. https://doi.org/10.1182/blood-2011-02-297325
  25. Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol 2011;90:423-428. https://doi.org/10.1007/s00277-010-1130-y
  26. Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol 2010;89:391-397. https://doi.org/10.1007/s00277-009-0841-4
  27. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-2011. https://doi.org/10.1172/JCI114392
  28. Papadaki H, Kyriakou D, Foudoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 1997;97:191-195. https://doi.org/10.1159/000203682
  29. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97:2440-2452. https://doi.org/10.1002/cncr.11072

Cited by

  1. Recent advances in multiple myeloma: a Korean perspective vol.31, pp.5, 2015, https://doi.org/10.3904/kjim.2015.408
  2. Dynamic monitoring of serum ferritin as an adverse prognostic biomarker in patients with multiple myeloma vol.15, pp.16, 2015, https://doi.org/10.2217/bmm-2020-0849